Century Therapeutics, Inc. · NASDAQ:IPSC
Century Therapeutics — Investor Presentation (November 2024)
31 slides from Century Therapeutics's investor presentation, Nov 5, 2024
Slide 1: November 2024 Corporate overview
November 2024 Corporate overview
Slide 2: Forward-looking statements
2 Forward - looking statements This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical f
Slide 3: Building an industry-leading, next-generation allogeneic iPSC-derived cell therapy platform
3 Century Therapeutics: Building an industry - leading, next - generation allogeneic iPSC - derived cell therapy platform Foundational investments in iPSC technology, genetic editing, protein engineering, and manufacturing Limitless Potential… Progressing differentiated clinical programs based on Al
Slide 4: Overview of foundational platform technologies
Overview of foundational platform technologies
Slide 5: Century's singular focus: best-in-class iPSC-derived cell therapies
5 Century’s singular focus: To deliver best - in - class iPSC - derived cell therapies Century platform enables the incorporation of critical features we b elieve can only be realized via iPSC - derived cell therapies Production from a master cell bank , compared to donor - derived or autologous cel
Slide 6: Next-generation allogeneic iPSC technology platform: versatility and unprecedented control
6 Century’s next - generation allogeneic iPSC technology platform: Versatility and unprecedented control Rapid Integration of major advances in product functionality and manufacturability iPSC iT cell iNK cell SINGLE CELL CLONING POST GENE EDITING AND CHARACTERIZATION DIFFERENTIATION Consistency Yie
Slide 7: Precision CRISPR MAD7 mediated sequential gene editing of iPSCs
7 Precision CRISPR MAD7 mediated sequential gene editing of iPSCs generates uniform product candidates Multiple gene edits (KO/KI) iPSC bank Engineered iPSC Master Cell Bank (MCB) Sequential selection steps iPSC Precision Engineering CRISPR - mediated HDR (MAD 7) Advantages of Century’s Platform Pre
Slide 8: Allo-Evasion edits + repeat dosing = potential greater durability
8 Allo - Evasion edits + repeat dosing = potential greater durability Potential to drive durable responses with engineering to resist immune rejection Next - wave of allogeneic cell therapies must solve for challenge of rejection With Allo - Evasion engineering Without Allo - Evasion engineering Dos
Slide 9: Advancing our leadership in Allo-Evasion technology
9 Advancing our leadership in Allo - Evasion technology Continuous improvement in holistic immune protection designed to overcome major pathways of host vs. graft rejection Allo - Evasion 1.0 Allo - Evasion 3.0 Allo - Evasion 5.0 Core edits disarm host cells from eliminating therapy • Deletion of β
Slide 10: Foundational investments in iPSC manufacturing
10 Foundational investments in iPSC manufacturing Developing fit - for - purpose products Established in - house manufacturing • Increased process and product consistency • Scalable platforms and optimized processes to maximize yield, reduce COGs, and meet demand • Increased cell fitness, as cells d
Slide 11: Century Therapeutics
THERAPEUTICS ©) CENTURY
Slide 12: Diversified pipeline spanning cell types and targets in cancer and autoimmune diseases
12 Collaborator Clinical IND - enabling Research Indications Targets iPSC Platform Product P3 P2 P1 Autoimmune diseases B cell - mediated Autoimmune diseases CD19 iNK CNTY - 101 Autoimmune diseases CD19 iNK / iT CNTY - 108 Autoimmune diseases CD19 iT CLDE - 308 Myasthenia Gravis BCMA iT CLDE - 361 H
Slide 13: Clinical programs
CNTY - 101 Clinical programs
Slide 14: Differentiated next-gen CD19 targeted product
14 CNTY - 101: Differentiated next - gen CD19 targeted product Only cell therapy with six precision gene edits currently in the clinic Delivering on our vision to change the cell therapy treatment paradigm • Goal to improve durability, tolerability and ease of outpatient administration • Potential t
Slide 15: Unmet need in R/R B-cell lymphomas and potential solution
15 R /R: Relapsed or Refractory, NHL: Non - Hodgkin Lymphoma, CAR - T: Chimeric Antigen Receptor T cell therapy 1 Cappell, Nature Reviews Clinical Oncology (2023) CNTY - 101 in relapsed/refractory B - cell lymphomas Aim : To deliver durable responses via repeat dosing facilitated by Allo - Evasion a
Slide 16: ELiPSE-1 Phase 1 trial design
16 1. Standard lymphodepletion regimen: fludarabine (30 mg/m/d) and cyclophosphamide IV (300 mg/m/d) for 3 days 2. Subjects who are assessed as stable disease or better may receive additional cycles of CNTY - 101 3. Subjects at DL4A did not receive IL - 2 on the day of CNTY - 101 infusion but di
Slide 17: ELiPSE-1 enrolled heavily pre-treated R/R B-NHL patients
17 1 As of 15 October 2024 data snapshot date, data collection ongoing 2 HRFL: High - risk Follicular Lymphoma; DLBCL: Diffuse large B cell Lymphoma; MZL: Marginal Zone Lymphoma; MCL: Mantle Cell Lymphoma Safety evaluable N = 20 Baseline characteristics 66 (51 – 80) Median age (range, years) 16 (80)
Slide 18: Clinical data snapshot: increased ORR at higher dose with favorable safety
18 CNTY - 101 clinical data snapshot Increased ORR at higher dose alongside a favorable safety profile As of 15 October 2024, data snapshot date, data collection ongoing, efficacy based on Lugano criteria | CR: Complete Response, ORR: Overall Response Rate, DLTs: Dose Limiting Toxicities, CRS: Cytok
Slide 19: Increasing exposure with dose and schedule
19 PBMC genomic DNA Plasma cell - free DNA Increasing CNTY - 101 exposure with dose and schedule • Extended persistence in circulation at dose level 4A (1 x 1e9 cell infusion) • Persistence outside the bloodstream was detected via a cell - free ( cf ) DNA assay beyond day 15 • Multiple infusions in
Slide 20: Lymphocyte counts and PK profile
20 • Lymphodepleting Chemotherapy (LDC) depleted patient NK/T cell counts and drove a transient spik e of IL - 15 cytokine • By post - infusion day 8 , NK/T cell counts, IL - 15 concentration returned to screening level • Similar PK profile observed for each CNTY - 101 infusion within a cycle despit
Slide 21: B-cell depletion and re-emergent B-cell profile
21 B - cell depletion Re - emergent B - cell profile Graphs show data from the initial cycle of all subjects who had B cell counts of 0.25 cell/ L or greater (N=10). ). Each line represents an individual subject. Data from a subject with supraphysiological levels of circulating malignant B cells was
Slide 22: ELiPSE-1 initial data: key takeaways
22 ELiPSE - 1 initial data: Key takeaways CR: Complete Response Heavily pretreated and refractory patient population treated in first - in - human dose escalation trial, including 45 % patients who had received prior CAR T treatments Favorable initial safety profile; can be delivered in an outpatien
Slide 23: Key differentiators in autoimmune disease treatment
23 Key differentiators of CNTY - 101 in autoimmune disease treatment CNTY - 101: CD - 19 targeted iNK cell therapy with 6 precision gene edits including Allo - Evasion technology • Ph1 CALiPSO - 1 trial in B cell - mediated autoimmune diseases (Systemic Lupus Erythematosus, Lupus Nephritis , Idiopat
Slide 24: Potential to drive B-cell depletion with tighter control over drug exposure
24 CNTY - 101: Potential to drive B - cell depletion with tighter control over drug exposure More potent than primary CAR - T at B - cell killing of SLE patient cells in preclinical comparison CNTY - 101 more potent than primary CAR - T cells at B - cell killing at 24 hours in preclinical comparison
Slide 25: Opportunity in moderate to severe autoimmune indications
25 Opportunity in moderate to severe autoimmune indications to provide long term, drug free remission 1. Izmirly 2017, Duarte - Garcia - 2022, Lim 2014, Dall’Era 2017 . Approximately 40% of SLE patients have Lupus Nephritis 2. Fan 2020, Bairkdar 2021 3. Smoyer - Tomic 2012, Bernatsky 2009 4 . Macken
Slide 26: CALiPSO-1 Phase 1 study in refractory B cell-mediated autoimmune diseases
26 CNTY - 101: CALiPSO - 1 (NCT06255028) refractory B cell - mediated autoimmune diseases Phase 1 study Inclusion: • Participants with moderate to severe SLE , LN, IIM or dcSSc with treatment - resistant and active disease, after 2+ standard immunosuppressive therapies Endpoints: • Key endpoints: Sa
Slide 27: Century Therapeutics
CENTURY THERAPEUTICS
Slide 28: Robust pre-clinical pipeline addressing barriers confronting cellular therapies
28 Century’s robust pre - clinical pipeline has potential to address critical barriers confronting cellular therapies Multiple iPSC - derived immune effector cells: iPSC - enabled engineering solutions: 28 Opportunity across multiple diseases: 1 • Cytokine engineering to reduce or eliminate lymp
Slide 29: Corporate position & upcoming milestones
Corporate position & upcoming milestones
Slide 30: Cash runway into 2H 2026
30 Cash runway into 2H 2026 Ended 3 Q 24 with cash, cash equivalents, and investments of $244.7M Cash resources Differentiated pipeline based on Allo - Evasion technology x Potential to overcome limitations of conventional allogeneic cell therapy Encouraging preliminary clinical data from Phase 1 tr
Slide 31: Building an industry-leading, next-generation allogeneic iPSC-derived cell therapy platform
31 Century Therapeutics: Building an industry - leading, next - generation allogeneic iPSC - derived cell therapy platform Foundational investments in iPSC technology, genetic editing, protein engineering, and manufacturing Limitless Potential… Progressing differentiated clinical programs based on A
Century Therapeutics — Investor Presentation (November 2024) on 6ix